Smiths Detection on Tuesday said it has completed its acquisition of PathSensors, a developer of biological detection technology used in defense, food safety and emerging disease applications.

Terms of the deal were not disclosed. Smiths Detection is part of Britain’s Smiths Group.

PathSensors, which is based in Baltimore, has bio-detection technology for detecting deadly pathogens. The company also says it has technology for aerosol detection of COVID-19.

“We are pleased to be able to complete this acquisition, which we view as a significant strategic step in accelerating how we are able to respond to biological threats, which are becoming increasingly relevant in the current environment,” Roland Carter, president of Smiths Detection, said in a statement. “PathSensors has developed such a capability. With its multiple threat assays already available, it is able to identify biological threats in minutes and will provide a suitable biological capability to our customers.”

Smiths Detection has strong legacy capabilities in chemical, radiological and explosive detection. PathSensors has a customer base similar to Smiths’ in the chemical threat detection space.